Shattuck Labs, Inc. Operating Lease, Payments
Shattuck Labs, Inc. (STTK) reported Operating Lease, Payments of $1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-05
- Shattuck Labs, Inc. operating lease, payments for the quarter ending 2022-12-31 was $300.00K.
- Shattuck Labs, Inc. operating lease, payments for the quarter ending 2022-09-30 was $200.00K.
- Shattuck Labs, Inc. operating lease, payments for the quarter ending 2022-06-30 was $300.00K.
- Shattuck Labs, Inc. operating lease, payments for the quarter ending 2022-03-31 was $200.00K.
- Shattuck Labs, Inc. operating lease, payments for fiscal 2025 was $1.10M, a 0.00% change from fiscal 2024.
- Shattuck Labs, Inc. operating lease, payments for fiscal 2024 was $1.10M, a 10.00% increase from fiscal 2023.
- Shattuck Labs, Inc. operating lease, payments for fiscal 2023 was $1.00M, a 0.00% change from fiscal 2022.
- Shattuck Labs, Inc. operating lease, payments for fiscal 2022 was $1.00M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.10M 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $1.10M 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $1.00M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $500.00K derived: sum of 2 quarters · filed 2023-02-23 | $800.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.00M 10-K · filed 2023-02-23 |
| 2022-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $500.00K derived: sum of 2 quarters · filed 2022-11-09 | $700.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $500.00K 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $200.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |